GO:1904447 folate import across plasma membrane

Folate import across plasma membrane (GO:1904447) is the biological process by which folic acid is moved from the extracellular space, across the plasma membrane, and into the cytosol. This process is essential because folates are hydrophilic vitamins that cannot diffuse freely through lipid bilayers and therefore depend on dedicated transport proteins. The reduced folate carrier SLC19A1 is a well-characterized human plasma-membrane transporter that recognizes folate and related antifolates, and its structure has been resolved with methotrexate bound, providing a molecular framework for understanding substrate recognition during import. Beyond its classical role in vitamin uptake, SLC19A1-mediated import of extracellular 2'3'-cGAMP establishes an antiviral response that limits herpes simplex virus-1 infection, demonstrating that this transport process intersects with innate immunity. The process is not limited to mammals. In bacteria, folate-specific energy-coupling factor (ECF) transporters use a bilayer-mediated toppling mechanism to move substrate across the membrane, as revealed by cryo-electron microscopy. In the malaria parasite Plasmodium falciparum, exogenous folate transport has been characterized biochemically, highlighting the importance of folate acquisition for proliferation of protozoan pathogens. These examples show that GO:1904447 encompasses mechanistically diverse systems unified by the same physiological outcome: delivery of folate to the cytosol. For researchers, GO:1904447 matters because folate import influences one-carbon metabolism, nucleotide biosynthesis, and drug response. Antifolates such as methotrexate depend on SLC19A1 for cellular entry, so transport activity directly shapes chemotherapeutic efficacy. In addition, pathogen-encoded or pathogen-targeted transport mechanisms can modulate host immune signaling, as shown by the interaction between herpes simplex virus-1 and the 2'3'-cGAMP importer SLC19A1. Understanding the genes, structures, and regulatory inputs of folate import is therefore relevant to cancer biology, infectious disease, and immunology.

In our own words, GO:1904447 describes the directed movement of folic acid from the exterior of a cell, across the plasma membrane, and into the cytosol. It is a biological process rather than a single molecular activity, because it requires a membrane-embedded transport system that recognizes extracellular folate and translocates it into the intracellular compartment. The QuickGO definition specifies that the movement is directed and that the destination is the cytosol, distinguishing this process from folate metabolism, folate receptor binding, or intracellular folate compartmentalization. Synonyms such as folate import into cell and folic acid import across plasma membrane capture the same directional, plasma-membrane-spanning event.

Folate import across plasma membrane is important because it supplies the cytosol with a vitamin that is required for one-carbon transfer reactions, nucleotide synthesis, and amino acid metabolism, and because it is the route by which antifolate drugs enter cells. The human reduced folate carrier SLC19A1 recognizes methotrexate, so the structural basis of folate import directly informs how chemotherapeutic antifolates are handled by cells. In parallel, the same transporter can import the immune messenger 2'3'-cGAMP, coupling folate transport to antiviral signaling and making it a point of intervention by viruses such as herpes simplex virus-1. In pathogens, folate acquisition supports proliferation, as shown for Plasmodium falciparum, and bacterial ECF transporters provide mechanistic insight into how folate-specific uptake can be achieved. Together, these findings place GO:1904447 at the intersection of nutrition, pharmacology, immunology, and infectious disease.

The following genes and proteins are directly implicated in folate import across plasma membrane or in mechanistically related transport systems described in the verified literature.

Folate import across plasma membrane is regulated at the level of transporter expression, substrate availability, and structural state. The substrate-bound structure of SLC19A1 with methotrexate provides a snapshot of a recognition-competent state, implying that conformational transitions govern transport activity. In bacterial ECF transporters, the toppling motion of the substrate-binding component is an intrinsic regulatory feature of the transport cycle. In the context of infection, herpes simplex virus-1 targets SLC19A1, effectively modulating the import pathway as an antiviral countermeasure. In Plasmodium falciparum, exogenous folate transport activity reflects the parasite's need to acquire folate from the environment, linking transport regulation to growth conditions. General import pathways, such as mitochondrial protein import mediated by Hsp70 complexes and glycosomal import of DHFR hybrid proteins, illustrate that membrane translocation steps are often controlled by dedicated chaperone and targeting systems.

SLC19A1 recognizes methotrexate, a widely used antifolate drug, and the structural basis of this recognition has been determined. Because methotrexate must enter cells to inhibit folate metabolism, changes in folate import capacity can influence drug response. Studying GO:1904447 therefore has direct implications for understanding how tumor cells and normal tissues handle antifolate chemotherapy.

SLC19A1 imports extracellular 2'3'-cGAMP, and this import establishes an antiviral response that limits herpes simplex virus-1 infection. Herpes simplex virus-1 in turn targets SLC19A1 as an antiviral countermeasure, indicating that the folate import pathway is a battleground in host-virus interactions. This connection expands the disease relevance of GO:1904447 beyond vitamin metabolism into infectious disease and innate immunity.

Plasmodium falciparum depends on exogenous folate transport, which has been characterized biochemically. Because folate is required for parasite proliferation, the transport step represents a potential vulnerability. Research on GO:1904447 in this organism may inform antimalarial strategies that target folate acquisition.

Direct measurement of folate import across plasma membrane typically uses radiolabeled or fluorescent folate derivatives and quantification of intracellular substrate over time. Such assays can be applied to cells expressing wild-type or mutant SLC19A1 to test the consequences of sequence changes on import activity. In Plasmodium falciparum, exogenous folate transport has been characterized biochemically, providing a template for pathogen-focused transport assays.

Cryo-electron microscopy and related structural methods reveal how folate transporters recognize substrate and move it across the membrane. The structure of human SLC19A1 with methotrexate bound defines the antifolate recognition site, while cryo-EM of a folate-specific ECF transporter captured a bilayer-mediated toppling mechanism. These approaches connect atomic-level conformations to the functional definition of GO:1904447.

CRISPR-based knockout, point mutation, and knock-in strategies allow researchers to test the causal role of transporter genes in folate import. For example, disrupting SLC19A1 can reveal its contribution to methotrexate uptake and antifolate sensitivity, and perturbing SLC19A1 can test its role in 2'3'-cGAMP import and antiviral responses. Such experiments link genotype to transport phenotype.

Because SLC19A1-mediated import of 2'3'-cGAMP establishes an antiviral response, infection models with herpes simplex virus-1 can be combined with transporter perturbation to measure immune activation and viral replication. These readouts extend the study of GO:1904447 into immunology and virology.

Researchers studying folate import across plasma membrane-related genes often need to determine whether a candidate gene is causally involved in transport, drug uptake, or immune signaling. EDITGENE provides CRISPR-based cell models and screening services that allow precise perturbation of transporters such as SLC19A1 and systematic interrogation of the genes that support GO:1904447.

GO:1904447, folate import across plasma membrane, defines a fundamental transport process that supplies cells with folate and shapes responses to antifolate drugs and immune messengers. The human reduced folate carrier SLC19A1 provides a structural and functional paradigm for substrate recognition and import, while bacterial ECF transporters and Plasmodium falciparum systems illustrate mechanistic and pathogenic diversity. The intersection of folate import with 2'3'-cGAMP-mediated antiviral immunity and viral countermeasures further broadens its biological significance. Continued research using transport assays, structural biology, and CRISPR-based models will clarify how this process is regulated and how it can be targeted in disease.